摘要
目的探析带状疱疹后神经痛的治疗方案,并结合普瑞巴林治疗以及其他药物开展对比试验,进而调研临床疗效。方法选取在鞍钢集团公司总医院门诊治疗的80例带状疱疹后神经痛患者作为研究对象,时间为2020年1月至2021年1月,以随机方式分为两组,每组40例。对照组患者口服卡马西平药物治疗,观察组患者口服普瑞巴林药物治疗,比较两组患者治疗前后疼痛程度、治疗效果及药物不良反应发生率。结果治疗前,两组患者的疼痛程度对比无差异(P>0.05);观察组患者的疼痛程度在治疗后1周、2周和4周均轻于对照组(P<0.05);观察组治疗总有效率显著高于对照组(P<0.05);两组均伴有轻度的嗜睡、头晕,观察组有1例患者因为眩晕退出研究。观察组患者用药不良反应发生率为15.38%,低于对照组的25.00%(P<0.05)。结论普瑞巴林用于治疗带状疱疹后神经痛患者的效果显著,可促使患者的疼痛症状尽快消失,且无严重不良反应,耐受性好。
Objective To explore the treatment of postherpetic neuralgia,and carry out comparative experiments combined with pregabalin treatment and other drugs,so as to investigate the clinical efficacy.Methods A total of 80 patients with postherpetic neuralgia who were treated in the outpatient department of our hospital from January 2020 to January 2021 were selected as the subjects of this study,and randomly divided into two groups,40 cases in each group.The control group was treated with carbamazepine orally,and the observation group was treated with pregabalin orally.The pain degree,treatment effect and the rate of adverse drug reaction were compared between the two groups before and after treatment.Results There was no statistically significant difference in the pain degree of the two groups of patients before treatment(P>0.05);the pain degree of the observation group was lighter than the control group at 1,2,and 4 weeks after treatment(P<0.05).The total effective rate of treatment in the observation group was significantly higher than that of the control group(P<0.05);both groups were accompanied by mild drowsiness and dizziness.One patient in the observation group withdrew from the study due to dizziness.The incidence of adverse drug reactions in the observation group was 15.38%,which was lower than 25.00%in the control group(P<0.05).Conclusion Pregabalin has a significant therapeutic effect on patients with postherpetic neuralgia,and is an effective measure to promote the disappearance of pain symptoms in patients as soon as possible.It has no serious adverse reactions and good tolerance.
作者
尤兴正
YOU Xingzheng(General Hospital of Angang Group Corporation,Anshan 114002,China)
出处
《中国医药指南》
2021年第31期89-91,共3页
Guide of China Medicine